DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million.
Ampyra (dalfampridine) extended release tablets, 10 mg, twice daily, were approved for use in the US in January 2010, and received conditional approval in Europe, where it is known as Fampyra, in July 2011.
Ampyra is marketed by Acorda Therapeutics, Inc. (Acorda), within the United States, and by Acorda’s licensee, Biogen IDEC, internationally.
Ampyra is the only FDA-approved therapy indicated to improve walking in people with multiple sclerosis; this was measured in clinical trials by an increase in walking speed.
Walking disability is one of the most common and debilitating symptoms of the disease. While other multiple sclerosis drugs work by decreasing the inflammatory processes that cause damage to the central nervous system, Ampyra, a potassium channel blocker, was shown in preclinical studies to enhance message conduction in damaged nerve fibers.
For further deal information visit Current Agreements (subscription required)
Related
Browse: Complete Current Partnering report catalog
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
